Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Qilu Hospital of Shandong University
Objective: To observe the clinical efficacy and safety of TF combined with/ without IGU for 30 weeks in patients with moderate to severe active RA with different clinical characteristics and subgroups by using a prospective cohort , and to find the best combination scheme of TF.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients who meet RA standards in 1987 and 2010 or ERA standards in 2012;
2. Age \> 18 years old;
3. the extrapulmonary manifestations of RA were stable;
4. Patients with NSAIDs tolerance;
5. DAS28-ESR is highergreater than 2.6.
You may not be if
Patients who meet any of the following criteria will be excluded from the study:
1. Patients with acute and chronic infection;
2. Platelet count \< 80\*10\^9/L, or white blood cell \< 3\*10\^9/L;
3. ALT or AST is 2 times higher than the upper limit of normal value;
4. Renal insufficiency: serum Cr ≥ 176 umol/L;
5. Pregnant or lactating women (breastfeeding);
6. Have a history of malignant tumor (the cure time is less than 5 years);
7. Patients with severe hypertension and cardiac insufficiency;
8. Other diseases or conditions in which immune suppressants cannot be used;
